The new NIA-supported EXERT study, in partnership with the YMCA, is looking to find the right dose of exercise to slow memory loss.
People spend about a third of their lives asleep. When we get too little shut-eye, it takes a toll on attention, learning and memory, not to mention our physical health. Virtually all animals with complex brains seem to have this same need for sleep. But exactly what is it about sleep that’s so essential?
As baby boomers age, an unprecedented number of people will be diagnosed with Alzheimer’s disease. The economic and social impacts will be wide reaching from cost of treatment to the effect on caregivers.
Read the exceptional compilation of AD-related data and statistics. Includes a Special Report on the Next Frontier of Alzheimer’s Research
In lieu of a crystal ball that can foresee Alzheimer’s, scientists are trying to divine impending disease by looking deep into a person’s genome.
Read “Rates of Cortical Atrophy in Adults 80 Years and Older With Superior vs Average Episodic Memory”
Held in the historic Austrian capital, the 13th AD/PD conference reflected a rapidly growing field. The meeting jammed science into five parallel sessions, with 545 talks running from early morning till late evening and some 1,200 posters vying for attention.
View the best moments of the 13th International Conference on Alzheimer’s & Parkinson’s Diseases. Mechanisms, Clinical Strategies, and Promising Treatments of Neurodegenerative Diseases
Memory loss in Alzheimer’s disease (AD) is attributed to pervasive weakening and loss of synapses. Here, we present findings supporting a special role for excitatory synapses connecting pyramidal neurons of the hippocampus and cortex with fast-spiking parvalbumin (PV) interneurons that control network excitability and rhythmicity.
A need exists for a simple, less-invasive test to diagnose Alzheimer’s disease and similar neurodegenerative conditions in living people, perhaps even before memory loss becomes obvious.
From WashPo for the layman, why we should be excited by the lymphatic system developments.
Read an overview of the substantial current and future economic impact of neurological disease, and an action plan for reducing this burden through neurological research and enhanced clinical management of neurological disorders in the US.
Presented, the Fiscal Year 2019 NIH Professional Judgment Budget for Alzheimer’s Disease and Related Dementias. Outlined at the July 28 meeting of the HHS Secretary’s Advisory Council on Alzheimer’s Research, Care, and Services.
JAMA Neurology reports on the differences in carriers of the “most potent genetic risk factor for Alzheimer’s disease” – the apolipoprotein E ε4 (APOE4) allele.
A family with an astonishing rate of Alzheimer’s disease may harbor a powerful new gene.
The Biohaven Pharmaceutical Holding Company Ltd. announced today its clinical trial collaboration with the Alzheimer’s Disease Cooperative Study (ADCS).
Dr Sadowski talks about the potential of the EXERT Study to help identify the right dose of exercise to offset memory loss for people at risk for Alzheimer’s disease
“Our results demonstrate that ApoE affects tau pathogenesis, neuroinflammation, and tau-mediated neurodegeneration independently of amyloid-β pathology. ApoE4 exerts a ‘toxic’ gain of function whereas the absence of ApoE is protective” David Holtzman, MD Washington University
What potential therapy reports out next? There are not a lot of large, late stage, Alzheimer’s trial results expected until 2019 (including Biogen’s aducanumab, Merck’s BACE- oriented verubecestat, and Lilly/AstraZeneca’s lanabecestat).
Alan Levey, MD, PhD, Director of Emory’s Alzheimer’s Disease Research Center, commented on the findings making news: “We were amazed to see the accumulation of LSD1 in neurofibrillary tangles in Alzheimer’s, and in TDP-43 aggregates in FTD” (Published in Nature Communications this week)